Abstract 488P
Background
Glioma, the most common malignancy of the central nervous system, is charactarised by its extensive proliferation and invasion. An increasing number of studies suggest that glioma stem cells (GSCs) are at the root of glioma's difficulty in control, treatment and recurrence. The adhesion molecule integrin α2 (ITGA2) plays an important role in regulating various biological behaviors such as cell migration, growth and differentiation. Previous studies have shown that ITGA2 is closely associated with tumor progression, but the role and mechanism of ITGA2 in regulating glioma progression and stemness remain unclear.
Methods
The gene expression profile of GSCs was analyzed by RNA-seq. ITGA2 expression in glioma tissues was examined by immunohistochemical staining, followed by analysis of the correlation between ITGA2 expression and clinical features. In addition, the effects of lentivirus-mediated RNA interference of ITGA2 on cell proliferation, cell migration, spheroid forming ability and cell stemness specific gene and protein expression in glioma cells were investigated.
Results
The expression level of ITGA2 was significantly increased in GSCs compared to glioma cells. ITGA2 protein expression was increased in high-grade glioma samples. Prognostic analysis showed that patients with high ITGA2 expression had shorter survival. In glioma cells, knockdown of ITGA2 significantly inhibited the proliferation, migration, invasion and spheroid forming ability of glioma cells. TCGA data analysis showed that ITGA2 expression positively correlated with the expression of stem cell-specific genes in gliomas. Knockdown of ITGA2 significantly reduced the expression levels of stem cell-specific genes and proteins in the cells. The molecular mechanism revealed that ITGA2 knockdown inhibited the activation of the AKT signaling pathway. The AKT phosphorylation activator SC79 reversed the reduced sphere-forming ability of glioma cells and the reduced expression levels of stem cell-specific genes and proteins in cells caused by ITGA2 knockdown.
Conclusions
Our findings elucidate the role and molecular mechanism of ITGA2 in regulating glioma progression and stemness, and provide new ideas for basic glioma research and tumor treatment strategies targeting GSCs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
576P - Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study
Presenter: Jifang Gong
Session: Poster session 16
577P - Results of the phase Ib study of NC410 combined with pembrolizumab in MSS/MSI-L colorectal cancer patients
Presenter: Eric Christenson
Session: Poster session 16
579P - Intratumoral fusobacterium as prognostic factor in early stage colorectal cancer: Results of the FUSOMAP study
Presenter: Paolo Nuciforo
Session: Poster session 16
581P - mRNA profiling as a biomarker of prognosis and response to first-line treatment in metastatic colorectal cancer: Discovery and validation of a gene expression signature in three randomized trials
Presenter: Marco Germani
Session: Poster session 16
582P - Prognostic role of macrophage infiltration and monocyte-to-lymphocyte ratio in stage III colon cancer: The MIRROR study
Presenter: debora basile
Session: Poster session 16
583P - COMPReS study: Multiomic profiling reveals organ-specific differences in metastases and identifies novel predictive biomarkers in relapsed localized colon cancer
Presenter: Blanca García-Mico
Session: Poster session 16
584P - Genomic and transcriptomic characterization of peritoneal, lung and liver metastases of colorectal carcinoma reveals site-specific differences
Presenter: Nerma Crnovrsanin
Session: Poster session 16
585P - Prospective validation of the metastatic colon cancer score (mCCS) in patients with RAS wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE
Presenter: Norbert Marschner
Session: Poster session 16